- Patent Title: Quinoxaline and pyridopyrazine derivatives as PI3K-beta inhibitors
-
Application No.: US16499421Application Date: 2018-03-29
-
Publication No.: US11130751B2Publication Date: 2021-09-28
- Inventor: Patrick René Angibaud , Olivier Alexis Georges Querolle , Didier Jean-Claude Berthelot , Christophe Meyer , Matthieu Philippe Victor Willot , Lieven Meerpoel , Thierry François Alain Jean Jousseaume
- Applicant: JANSSEN PHARMACEUTICA NV
- Applicant Address: BE Beerse
- Assignee: JANSSEN PHARMACEUTICA NV
- Current Assignee: JANSSEN PHARMACEUTICA NV
- Current Assignee Address: BE Beerse
- Priority: EP17163625 20170329
- International Application: PCT/EP2018/058175 WO 20180329
- International Announcement: WO2018/178280 WO 20181004
- Main IPC: C07D413/14
- IPC: C07D413/14 ; C07D495/10 ; A61P35/00
Abstract:
The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3Kβ inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
Public/Granted literature
- US20200181132A1 QUINOXALINE AND PYRIDOPYRAZINE DERIVATIVES AS PI3K-BETA INHIBITORS Public/Granted day:2020-06-11
Information query
